Category Archives: Biotechnology

To get a sense of who is truly in control of Nautilus Biotechnology, Inc. (NASDAQ:NAUT), it is important to understand the ownership structure of the business. We can see that individual insiders own the lion's share in the company with 33% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).

And looking at our data, we can see that insiders have bought shares recently. So the news of stock price falling by 18% is not something they might have been expecting soon after purchasing shares.

Let's take a closer look to see what the different types of shareholders can tell us about Nautilus Biotechnology.

Check out the opportunities and risks within the US Life Sciences industry.

Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.

Nautilus Biotechnology already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. When multiple institutions own a stock, there's always a risk that they are in a 'crowded trade'. When such a trade goes wrong, multiple parties may compete to sell stock fast. This risk is higher in a company without a history of growth. You can see Nautilus Biotechnology's historic earnings and revenue below, but keep in mind there's always more to the story.

Nautilus Biotechnology is not owned by hedge funds. Because actions speak louder than words, we consider it a good sign when insiders own a significant stake in a company. In Nautilus Biotechnology's case, its Top Key Executive, Parag Mallick, is the largest shareholder, holding 17% of shares outstanding. In comparison, the second and third largest shareholders hold about 14% and 14% of the stock. Interestingly, the third-largest shareholder, Sujal Patel is also a Member of the Board of Directors, again, indicating strong insider ownership amongst the company's top shareholders.

Our research also brought to light the fact that roughly 52% of the company is controlled by the top 4 shareholders suggesting that these owners wield significant influence on the business.

While studying institutional ownership for a company can add value to your research, it is also a good practice to research analyst recommendations to get a deeper understand of a stock's expected performance. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.

The definition of an insider can differ slightly between different countries, but members of the board of directors always count. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.

Our most recent data indicates that insiders own a reasonable proportion of Nautilus Biotechnology, Inc.. Insiders own US$78m worth of shares in the US$238m company. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.

The general public, who are usually individual investors, hold a 12% stake in Nautilus Biotechnology. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private equity firms hold a 27% stake in Nautilus Biotechnology. This suggests they can be influential in key policy decisions. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

We can see that Private Companies own 3.3%, of the shares on issue. It might be worth looking deeper into this. If related parties, such as insiders, have an interest in one of these private companies, that should be disclosed in the annual report. Private companies may also have a strategic interest in the company.

While it is well worth considering the different groups that own a company, there are other factors that are even more important. To that end, you should learn about the 3 warning signs we've spotted with Nautilus Biotechnology (including 2 which can't be ignored) .

If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Find out whether Nautilus Biotechnology is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.

More:
After buying recently, Nautilus Biotechnology, Inc. (NASDAQ:NAUT) insiders must be dismayed to see the company's market cap drop to US$238m - Simply...

The Industrial Biotechnology Innovation Centre (IBioIC) has appointed a new senior business engagement manager to accelerate the growth of Scotlands bioeconomy and achieve ambitious targets set out in the National Plan for Industrial Biotechnology.

Andrew Bowen joins IBioIC from Oxford University Innovation, where he was a senior licensing and ventures manager, focusing on commercialising a variety of high-impact chemistry and life sciences projects. Additionally, he led the formation of spin-outs from Oxford University, helping them develop their business plan, build teams and secure seed funding.

Andrew Bowen, senior business engagement manager at The Industrial Biotechnology Innovation Centre (IBioIC)

Since 2016, Andrew has also been a board observer at Oxford University spin-out company EnzBond Limited, which aims to change the current understanding of biocatalysts.

In his new role, Andrew will lead Biotech Innovators a new accelerator programme for SMEs, spinouts and start-ups launched earlier this month. He will also help to raise awareness of funding opportunities for companies in the IBioIC network and accelerate the commercialisation of strategic projects throughout the sector.

Andrew Bowen said: Im excited to join IBioIC and apply my experience across its range of projects. The innovation centres network includes so many fantastic companies using cutting-edge techniques and processes, and Im looking forward to connecting with them and exploring how IBioIC can support them further. Biotechnology presents a great opportunity to embrace the net zero targets for Scotland and Im keen to be part of the great work IBioIC does to reach these goals.

Mark Bustard, CEO of IBioIC, added: Andrew is an excellent addition to IBioIC. Having managed a large portfolio of projects within the chemistry and life sciences sectors in his role at Oxford, he brings a wealth of experience to the team. IBioICs main objective is to grow the bioeconomy in Scotland and Andrew will play a key role in connecting research teams with industry partners. We look forward to working with him as we continue to support companies in their journey towards net zero.

Read more of our People & Skills articles here

Follow this link:
IBioIC strengthens team with appointment from Oxford University Innovation - The Manufacturer

NEWPORT BEACH, Calif.--(BUSINESS WIRE)--ROTH Capital Partners (ROTH), http://www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Kumaraguru Raja has joined the firms healthcare research team, as Managing Director, Senior Research Analyst covering biotechnology. His research coverage is expected to include micro-cap and small-cap Biotechnology companies across the therapeutic space, with an initial focus on companies developing novel drugs for infectious diseases, inflammatory diseases, neurological disorders, oncology, and womens health.

Prior to joining ROTH, Dr. Raja was a senior biotechnology analyst at Brookline Capital Markets from 2017 to 2022, where he focused on small and microcap companies. He started his equity research career in 2010 as a Senior Associate Analyst on the Citi Research biotechnology team covering large-cap biotechnology companies. His expertise includes bottom-up scientific and financial analysis on companies across therapeutic areas and across a spectrum of market capitalizations. He focuses on drug development, intellectual property, FDA and EMA regulations, reimbursement coverage and clinical science. He conducted postdoctoral research at Mayo Clinic on the epigenetic causes of cancer and at Los Angeles Biomedical Research Institute on the molecular mechanisms concerning the role of human bone marrow stem cells in normal and leukemic hematopoiesis. He received a Ph.D. in Biological Sciences from Bowling Green State University and an MBA from University of California, San Diego.

Jeff Martin, CFA - Director of Research, commented, ROTH continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform. Im pleased to welcome Kumar to our thought-leading biotechnology research team. His strong academic background combined with his experience covering innovative and underappreciated biotechnology companies will undoubtedly serve our clients well.

Dr. Raja commented, I am enthusiastic to join ROTH, a highly regarded investment bank with a strong track record in healthcare. I am very impressed by the quality and depth of the ROTH research portfolio. My goal is to provide a significant contribution by analyzing companies to identify unique companies developing innovative treatments for diseases with significant unmet need with favorable risk-reward for investors.

We are excited to have Kumar on our healthcare research team, said Byron Roth, CEO of ROTH. His addition further demonstrates our unwavering commitment to the life sciences sector. Im confident that Kumars expertise in biotechnology will enhance our ability to continue to build upon our over 10-year track record of success in assisting both companies and investors in the healthcare sector.

Since 2010, ROTH has been involved in approximately 550 transactions for its Healthcare clients, with total transaction value over $24.8 billion. (Source: ROTH Capital Partners | 09/29/2022)

About Roth Capital Partners, LLC:

ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.

Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit http://www.roth.com.

More:
ROTH Capital Partners Announces the Addition of Kumaraguru Raja, Ph.D. to its Healthcare Research Team - Business Wire

The most recent report published by Market Research Inc. indicates that the Animal Health Biotechnology Market is likely to accelerate significantly in the next few years. Specialists have studied market drivers, restraints, risks and prospects in the global market. The Animal Health Biotechnology Market report shows the likely direction of the market in the coming years along with its assessments. A meticulous study purposes to understand the market price. By analyzing the competitive landscape, the authors of the report have made excellent efforts to help readers understand the key business strategies that significant organizations are utilizing to keep up with market sustainability.Biotechnology utilized in animal healthcare dates back to 19th century when the first vaccines were prepared for its use in animals. Considerable progress in the animal health biotechnology took place recently when biotechnology applications were utilized in both detecting and treating various infectious and parasitic diseases of animals.

Key Players in the Animal Health Biotechnology Market Research Report:Bayer AG, Merck & Co.Inc., Pfizer Inc., Sanofi, Santa Cruz Biotechnology

Get a Sample Copy of Report: https://www.marketresearchinc.com/request-sample.php?id=115348

The report includes organizational profiles of virtually all major players in the Animal Health Biotechnology market. The Company Profiles segment provides important analysis of strengths and weaknesses, business trends, recent advances, mergers and acquisitions, expansion plans, global presence, market presence, and portfolios of products from significant market players. This data can be used by players and other market members to expand their productivity and streamline their business strategies.

By Type:Feed AdditivesPharmaceuticalsVaccines

By Application:Production AnimalsCompanion Animals

:The research report extensively lists the regional landscape of this industry. According to the review, Animal Health Biotechnology Market regional landscape is bifurcated into , , , , and .The study provides significant data relating to the market share that every region is estimated to hold, in tandem with the growth opportunities anticipated for each geography.The report describes the growth rate in which each geography is estimated to register over the forecast time period.

Get Exclusive Discount: https://www.marketresearchinc.com/ask-for-discount.php?id=115348

The global market for Animal Health Biotechnology is segmented on the basis of product, type. These segments have been concentrated separately. The detailed examination permits evaluation of the factors influencing the Animal Health Biotechnology Market. Specialists have analyzed the nature of growth, investments in research and development, changing utilization patterns, and rising number of applications. Furthermore, experts have additionally assessed the changing economics around the Animal Health Biotechnology Market that are likely affect its course.

The report's regional analysis segment allows players to focus on high-growth regions and countries that could help them to expand their presence in the Animal Health Biotechnology market. Aside from expanding their footprint in the Animal Health Biotechnology market, the regional analysis assists players to increase their sales while having a better comprehension of customer behavior in specific regions and countries. The report provides CAGR, revenue, production, consumption and other significant measurements and figures related to the global and regional markets. It shows how different type, application, and regional segments are advancing in the Animal Health Biotechnology market in terms of growth.

Some of the Key benefit in the report:Which are the five top players of the Animal Health Biotechnology market?How might the Animal Health Biotechnology showcase change in the following five years?Which item and application will take a largest part of the Animal Health Biotechnology showcase?What are the drivers and limitations of the Animal Health Biotechnology market?Which local market will show the most elevated development?What will be the CAGR and size of the Animal Health Biotechnology market all through the estimate period?

Enquire before purchasing this report: https://www.marketresearchinc.com/enquiry-before-buying.php?id=115348

To know more about the Market Research Inc. Reports

Non-Bank Trade Finance Market https://www.digitaljournal.com/pr/non-bank-trade-finance-market-swot-analysis-business-growth-opportunities-by-top-companies-coface-trade-finance-global-clear-treasury-ccrmanager-bny-mellon

Finance Lease Market https://www.digitaljournal.com/pr/finance-lease-market-current-trends-future-aspect-analysis-2022-2030-hsbc-bank-sumitomo-mitsui-finance-and-leasing-bnp-paribas-leasing-solutions

Digital English Language Learning Market https://www.digitaljournal.com/pr/digital-english-language-learning-market-recent-trends-future-growth-high-demand-and-forecasts-2030-berlitz-languages-pearson-elt-sanako-corporation-ef-education-first-inlingua

Smart Waste Collection Market https://www.digitaljournal.com/pr/smart-waste-collection-market-analysis-share-size-recent-trends-and-demand-and-forecast-2030-bigbelly-inc-bin-e-covanta-holding-corporation-ecube-labs-co-ltd

Customization of this Report: This report can be customized as per your needs, Please contact our sales professional (sales@marketresearchinc.com), we will ensure you obtain the report which works for your needs

Contact UsMarket Research IncAuthor: KevinUS Address: 51 Yerba Buena Lane, Ground Suite,Inner Sunset San Francisco, CA 94103, USACall Us: +1 (628) 225-1818Write Us: sales@marketresearchinc.com

About UsMarket Research Inc. is farsighted in its view and covers massive ground in global research. Local or global, we keep a close check on both markets. Trends and concurrent assessments sometimes overlap and influence the other. When we say market intelligence, we mean a deep and well-informed insight into your products, market, marketing, competitors, and customers. Market research companies are leading the way in nurturing global thought leadership. We help your product/service become the best they can with our informed approach.

This release was published on openPR.

Read more from the original source:
Animal Health Biotechnology Market Growth Prospects, Trends and Forecast up to 2030 - openPR

The 16th Edition of the Pan-Asia Farmers Exchange Program started on October 10, 2022, and will last until October 14, 2022, in the Philippines. The program is organized to provide a platform for knowledge sharing and exchange on agricultural plant biotechnology.

Several participants including farmer leaders, scientists, academia, media, government officers, and policymakers will be present at this week-long program.

The 14th and 15th editions of the Pan-Asia Farmers Exchange Program held in 2020 and 2021 respectively, were held virtually.

Founder and Editor-in-Chief, Krishi Jagran, M C Dominic addressed the 16th Edition of Pan-Asia Farmers Exchange Program today in the Philippines. While addressing who's who, he stressed upon bringing the technology that can increases farm income.

Today, the second day of this program witnessed many eminent speakers sharing experiences and knowledge on biotech.

Ma. Lorelie Agbagala, Head of the Secretariat of the National Committee on Biosafety of the Philippines talks about the Philippine Biosafety Regulations on Plants derived from Modern Biotechnology.

Dr. Lilia Portales, Supervising Agriculturist at the Philippine Department of Agriculture- Bureau of Plant Industry, shares the Insect Resistance Management for Biotech Corn.

Jerome Barradas, Project Coordinator of the Research and Thought Leadership Department at SEARCA, discusses about Communicating Biotechnology.

Jenny Panopio, Chair of the CropLife Philippines Seeds Team, shared Philippine experiences in communicating biotechnology.

David Cristobal, Chair of the CropLife Philippines (CLP) Stewardship and Responsible Care Committee, talks about CLP's stewardship programs focusing on the Sustainable Corn Production in Sloping Areas and Use of Authorized Seeds.

First published on: 11 Oct 2022, 11:17 IST

Dear patron, thank you for being our reader. Readers like you are an inspiration for us to move Agri Journalism forward. We need your support to keep delivering quality Agri Journalism and reach the farmers and people in every corner of rural India. Every contribution is valuable for our future.

Originally posted here:
Experts at 16th Edition of Pan-Asia Farmers Exchange Program Discusses About Agriculture Biotechnology - Krishi Jagran

Granting legal rights and protections to non-human entities such as animals, trees and rivers is essential if countries are to tackle climate breakdown and biodiversity loss, experts have said.

The authors of a report titled Law in the Emerging Bio Age say legal frameworks have a key part to play in governing human interactions with the environment and biotechnology.

Ecuador and Bolivia have already enshrined rights for the natural world, while there is a campaign to make ecocide a prosecutable offence at the international criminal court. The report for the Law Society, the professional body for solicitors in England and Wales, explores how the relationship between humans and mother earth might be recalibrated in the future.

Dr Wendy Schultz, a futurist and report co-author, said: There is a growing understanding that something very different has to be done if our children are going to have a planet to live on that is in any way pleasant, much less survivable, so this is an expanding trend. Is it happening as fast as any of us would want? Possibly not, which is why its important to get the word out.

Her co-author, Dr Trish OFlynn, an interdisciplinary researcher who was previously the national lead for civil contingencies at the Local Government Association, said legal frameworks should be fit for a more than human future and developments such as genetic modification or engineering. This means covering everything from labradors to lab-grown brain tissue, rivers to robots.

We sometimes see ourselves as outside nature, that nature is something that we can manipulate, said OFlynn. But actually we are of nature, we are in nature, we are just another species. We happen to be at the top of the evolutionary tree in some ways, if you look at it in that linear kind of way, but actually the global ecosystem is much more powerful than we are. And I think thats beginning to come through in the way that we think about it.

An example of a right might be evolutionary development, where a species and individual is allowed to reach its full cognitive, emotional, social potential.

Such a right could apply to sows in intensive pig farming, calves taken away from their mothers and even pets, said OFlynn, adding: I say that as a dog lover. We do constrain their behaviour to suit us.

Developments in biotechnology also pose questions about the ethics of bringing back species from extinction or eradicating existing ones. Scientists are exploring reintroducing woolly mammoths and there has been discussion of wiping out mosquitoes, which carry malaria and other diseases.

The planet's most important stories. Get all the week's environment news - the good, the bad and the essential

We arent wise enough to manage all of these capabilities and to manage the ripple effects of decisions we make about our relationship with the living environment, said Schultz. Part of the issue is embedding some sort of framework for accountability and responsibility for the consequences of these things we do, and thats where law comes in.

The authors acknowledge potential resistance from very different traditions and beliefs in some western countries, compared with Ecuador and Bolivia, where rights to nature were granted under socialist governments and influenced by Indigenous beliefs (as was the 2019 ban on climbing Uluru in Australia).

Granting something that is culturally numinous rights just so you can preserve it gets us to a kind of valuation that, among other things, is a cultural shift away from the Judeo-Christian great chain of being dominion over nature, said Schultz. This is reconfiguring it to place us where we have always been and where we should be thinking of ourselves as belonging, as just a node in this greater web of life on the planet.

If that worldview can be enshrined in law, essentially granting personhood rights to the spirit of the river, the spirit of the trees or the spirit of the elephant, youre talking about enshrining a kind of neo-pantheism into 21st-century legal frameworks.

See more here:
Give legal rights to animals, trees and rivers, say experts - The Guardian

DUBLIN--(BUSINESS WIRE)--The "Oligonucleotide Synthesis Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

The oligonucleotide synthesis market is expected to register a CAGR of 12.3% during the forecast period 2022-2027

The growth of the oligonucleotide synthesis market is due to the increasing government investments and R&D expenditure in pharmaceutical and biotechnology companies and the use of synthesized oligonucleotides in molecular diagnostics and clinical applications.

The usage of synthetic oligonucleotides has been increasing rapidly over the past decade, owing to several benefits offered by molecular diagnostics and growing clinical applications. The nucleic acid application techniques are the reference methods. They are very useful for carrying out molecular diagnosis in several diseases, like the detection of infectious diseases, such as hepatitis.

For instance, In January 2020, the Department of Biotechnology (DBT) initiated the "Genome India Project" (GIP). The project aims to collect 10,000 genetic samples from citizens across India to build a reference genome. Some focus areas of this project are precision health, rare genetic disorders, mutation spectrum of genetic & complex diseases in the Indian population, genetic epidemiology of multifactorial lifestyle diseases, and translational research.

In addition to this, in February 2021, the Centre for Process Innovation (CPI) launched a project in the Medicines Manufacturing Innovation Centre in the United Kingdom. This project aims to revolutionize the manufacturing of oligonucleotides through a collaboration with AstraZeneca, Exactmer, Novartis, and the United Kingdom Research & Innovation.

Inclisiran, a small interfering RNA used in the treatment of atherosclerotic cardiovascular disease (ASCVD), would be the first medicine produced at a commercial scale as a result of this collaboration. Synthetic oligonucleotides also have significant clinical applications, primarily for the detection of autoimmune antibodies. There have been consistent developments in synthetic biology over the past few years, where synthetic oligonucleotides were used to develop assays for the detection of anti-double-stranded DNAs. Thus, all these factors are responsible for the growth of the oligonucleotide synthesis market.

However, there have been various instances in the past wherein, due to high complexities such as severe side effects, many drugs have been withdrawn or have failed in clinical trial phases. Such instances could become recurrent and may restrain market growth to a certain extent.

Key Market Trends

The Therapeutic Application Segment is Expected to Grow during the Forecast Period

Oligonucleotide therapeutics, which include antisense oligonucleotides, small interfering RNAs, and aptamers, show promising clinical outcomes for disease indications such as Duchenne muscular dystrophy, familial amyloid neuropathies, and macular degeneration. The increasing number of Food and Drug Administration-approved drugs and a rich clinical pipeline of oligonucleotide-based drugs are factors expected to drive the growth of these therapeutics in the coming years.

The increasing applications of oligos as therapeutic agents (such as antisense oligos and siRNA) used in treating neurological, infectious, and rare genetic disorders are expected to drive market growth.

Oligonucleotide therapeutics is an emerging drug modality, which consists of modified or unmodified short nucleic acid molecules, and includes antisense oligonucleotides (ASOs), small interfering RNA (siRNAs), microRNA (miRNAs), aptamers, and DNAzymes. For instance, as per the study published by the National Library of Medicine in March 2021, titled 'Recent Advances in Oligonucleotide Therapeutics in Oncology', currently, oligonucleotide therapeutics investigated in clinical trials include ASOs, siRNAs, miRNAs, aptamers, and DNAzymes. Their mechanisms of action differ, resulting in the correction of either abnormal expression or splicing patterns.

In addition to this, in March 2020, viltolarsen, developed by Japanese companies, was approved as a treatment for Duchenne muscular dystrophy. Moreover, in June 2022, GSK plc presented promising interim results from the B-Clear phase IIb trial showing that bepirovirsen, an investigational antisense oligonucleotide treatment for hepatitis B, reduced levels of hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA after 24 weeks' treatment in people with chronic hepatitis B (CHB). Such investigations are expected to boost the segment's growth in the years to come.

Nucleic acid-based therapeutics that regulate gene expression have been developed for clinical use at a steady pace for several decades, but in recent years the field has been accelerating and hence have, contributed to the segment's strong growth.

Market Dynamics

Market Drivers

Market Restraints

Key Topics Covered:

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

5 MARKET SEGMENTATION (Market Size by Value - USD million)

6 COMPETITIVE LANDSCAPE

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/jzzw3u

The rest is here:
Oligonucleotide Synthesis Market Report 2022: Increasing Government Investments and R&D Expenditure in Pharmaceutical and Biotechnology Companies...

In power since sweeping to victory in 2018, Mexican center-left president Andrs Manuel Lpez Obrador (AMLO) has relentlessly targeted conventional farming techniques, especially the growing and import of GMO food and animal feed. This policy reversal enraged most farmers but emboldening activist and indigenous groups that supported AMLO during the campaign.

His target: Crops modified to reduce the use of more toxic herbicides and dramatically reduce the spraying of insecticides has helped spur increased yields in many other countries.

AMLOs sharp policy reversal cites cultural concerns. He and his supporters among the organic and regenerative agriculture lobbies claim that GM crops are dangerous incursions into indigenous agriculture and its broader culture. His new policies, he claimed, would:

contribute to food security and sovereignty and protect native corn, cornfields, bio-cultural wealth, farming communities, gastronomic heritage and the health of Mexicans.

Whether AMLO succeeds with this GMO rejectionist policy remains a huge question mark. He launched this initiative in a 2020 New Years Eve decree. Mexico previously had halted all official biotechnology food or feed product approvals in 2018 but this new proposed policy went much further. He issued two presidential edicts phasing in bans on the herbicide glyphosate and genetically modified corn to full take effect by 2024. [GM corn and select other crops are modified to be resistant to the weedkiller, making pest control far easier and less expensive.]

Obrador also soon announced a three-year phaseout of the import of GM yellow corn for human consumption. Mexico, one of the largest buyers of US corn, has evolved a close partnership with Canada and the US. The grain trade between the US and Mexico has such importance that there are specific considerations in the inter-country agreement to protect farmers and their interests.

Its not clear whether the phased-in ban would also extend to the import of corn for cattle feed. Under NAFTA and its successor the three-headed trade agreement between Canada, the US and Mexico known as CUSMA, USMCA and T-MEC the United States has seen a 400% increase in corn exports to Mexico, the vast majority of it genetically modified yellow dent corn (also known as grain corn, a type of field corn with a high soft starch content).

Some Mexican officials say imports of US-grown GMO yellow corn for animal feed will continue but American farmers are skeptical noting there is no official Mexican document assuring them that these imports wont be banned as well.

Banning the import of US-grown GM corn would significantly affect US farmers and roil the food market. Closing the Mexican market to US corn could send corn prices in the US down sharply, which would be particularly painful for corn-belt states.

US Agriculture Secretary Tom Vilsack says he has discussed this issue with Obrador, stressing that halting corn shipments would hurt Mexican consumers, particularly the poor.

I informed him about the importance of understanding the role of biotechnology, the role of production and the connection with his livestock industry, Vilsack said, adding that an inconsistent message from Mexico on biotechnology could chill innovation in the sector.

But the political and activist opposition to GM and gene-edited crop varieties is fierce, led by the extremist edge of the environmental movement, mostly US-based lobby groups. For example, Pesticide Action Network, one of many advocacy groups that reject conventional agriculture and the use of genetically modified seeds, has praised the ban as a huge win for small farmers and Native communities.

PANs Mexican partner, Red de Accin sobre Plaguicidas y Alternativas en Mxico (RAPAM), hailed the decision as a cultural, enviornmental and economic victory:

[I]n order to achieve self-sufficiency and food sovereignty, our country must focus on establishing a sustainable and culturally appropriate agricultural production, through the use of practices and agroecological inputs that are safe for human health, the countrys biocultural diversity and the environment, as well as congruent with the agricultural traditions of Mexico.

Twenty months after the president announced his plan, global farming and food production are in disarray as the result of war disruptions and escalating climate events. Consequently, many Mexican farmers are having second thoughts, beset with uncertainty as agriculture officials and trade groups assess the likely negative impacts of GM crop bans, including a disruption in the Mexican food chain.

A recent report released by World Grain showed that Mexico imports approximately 17M tons/year of GM corn with the US as top supplier. A ban could increase Mexicos food insecurity and add $4.4bn to its corn imports costs.

The impact on the poor could be catastrophic if the world food crisis continues or worse, escalates. Mexico is already not a food self-sufficient nation. As Ive previously written:

Mexico is the sixth largest producer of maize in the world, but it is also a major consumer of this crop. Even though domestic production traditionally met the entire demand for white maize, the country currently has to import more than 5 million tons of white maize and 8.15 million tons of yellow maize, representing a 45 percent deficit.

If prices rise as they inevitably would under these new policies, a high percentage of the Mexican population would be unable to afford nutritious food. As the MAIZALL delegation (which includes members from the Brazilian Association of Corn Producers, Argentine Corn and Sorghum Association, the National Corn Growers Association and US Grains Council) recently noted:

It is unlikely that enough non-GM corn would be available in international markets by 2024 to meet Mexicos need, leading to food insecurity and increased prices for many of the countrys staple foods.

The AMLO Administration is selling this policy turn as the best way to protect Mexican biodiversity and culture. As political speech, it works. He and his supporters firmly believe that an increase in organic farming, as well as the adoption of ancient farming techniques such as milpa (a system in which different species coexist, sharing resources like water, light, soil and even ecological interactions, such as the nitrogen fixation provided by beans), are enough to achieve self-sufficiency in this fast-growing nation, now with 121 million people.

But farm experts and agricultural economists say there is no way to satisfy the national demand for corn by relying just on national production.

This decree is completely divorced from reality, said Jos Cacho, president of Mexicos corn industry chamber CANAMI, the 25-company group that includes top corn millers like Gruma, cereal maker Kellogg and commodity trader Cargill.

There is early evidence that the ban of glyphosate, which is being phased in, has already cut yields, with no tangible benefits to the environment or Mexican farmers. The bans have also sparked the formation of a huge black market for illegal herbicides.

Considering the key role GM corn exports have traditionally played in the state economy, a huge drop-off in maize production courts an economic disaster. A self-imposed economic contraction linked to restrictions on crop biotechnologies could position the country for a Sir Lanka-like collapse, as GM corn is deeply attached to the overall Mexican economy. The ban would disrupt well-established supply chains, from livestock to a dizzying array of condiments and sauces that use starches derived from the corn, according to Jose Cacho president of Mexicos corn industry chamber of commerce.

There is no government strategy to prepare for the unintended consequences of this sharp policy reversal. Mexico has not invested in research and development to provide alternatives for effective and inexpensive glyphosate, which almost all mainstream scientists and most farmers agree is the safest, most effective, and least costly herbicide on the market.

Obradors decree has also exacerbated internal ideological tensions, and it comes at a time when food security has emerged as one of the worlds most pressing issues. While his politics may play well in a country struggling economically, it will not help Mexico avoid a sizable food crisis largely of its own making.

Worse, this crisis comes at a time when there are emerging signs that there is not enough farmland in Mexico to satisfy domestic demand especially because of the lower yields generated by organic techniques. The yield lag runs as high as 9.5 bushels per acre for corn, the difference between losing money and surviving. A recent Purdue University study found conventional GM corn yields 32% more corn per acre.

This a case in which no one appears to benefit from what seems like a manufactured crisis. As recently reported in El Economista, US farmers have started to lobby in Washington, urging the government to protect their vulnerable farms. Washington could raise a dispute under the trade agreement clauses that address cooperation between members over regulation of individual government imports. Its not at all clear that the standing agreements will be enforced, and or if Mexico will be allowed to renege on its agreements.

Its precisely at this moment that GM corn varieties, home grown and imported, could help stabilize the economy. A state-of-the-art 2018 meta-analysis of two decades of field data on maize found planting GM variety seeds led to a yield increase of as much as 25%, while dramatically lowering the presence of health-endangering mycotoxins and other crop pests.

Despite the efforts of farmers associations and seed companies, and legal challenges, the government posture is unlikely to change anytime soon. There is fleeting hope that an alliance between chagrined scientists, disgruntled farmers and worried consumers could put pressure on Obrador to reconsider.

As the politicization of crop biotechnology has unfolded in Mexico City, the countrys crop science community has redoubled its research efforts in hopes the country will strike a better balance between innovation and cultural heritage. Key is embracing next generation GMOS and gene editing crops by relaxing strangulating regulations.

National research centers such as the CINVESTAV are developing highly productive strains of corn resistant to droughts and low temperatures. This novel variety was tested in the lab and proved to be fully functional in the field. But due to current restrictions on GM corn, this variety, like all other Mexican-developed GM crops, will remain in the laboratory and banned for use by Mexican farmers.

Luis Ventura is a biologist with expertise in biotechnology, biosafety and science communication, born and raised in a small town near Mexico City. He is a Plant Genetic Resources International Platform Fellow at the Swedish University of Agricultural Sciences. Follow him on Twitter@luisventura

Continue reading here:
Viewpoint: Once a biotechnology innovator, Mexico puts its farm economy in a vise, jeopardizes grain trade with the US with GMO and herbicide bans -...

DUBLIN, Sept. 29, 2022 /PRNewswire/ -- The "Global White Biotechnology Market (2022-2027) by Product, Application, and Geography, with Competitive Analysis, Impact of COVID-19, and Ansoff Analysis" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The Global White Biotechnology Market is estimated to be worth USD 208 million in 2022, and is expected to reach USD 241.36 million by 2027, growing at a CAGR of 3.02%.

Market Segmentation

The Global White Biotechnology Market is segmented based on Product, Application, and Geography.

By Product, the market is classified into Biofuels, Biomaterials, Biochemicals, and Industrial Enzymes.

By Application, the market is classified into Cardiovascular, Neurovascular, and Urology.

By Geography, the market is classified into Americas, Europe, Middle-East & Africa and Asia-Pacific.

Countries Studied

America (Argentina, Brazil, Canada, Chile, Colombia, Mexico, Peru, United States, Rest of Americas)

Europe (Austria, Belgium, Denmark, Finland, France, Germany, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden, Switzerland, United Kingdom, Rest of Europe)

Middle-East and Africa (Egypt, Israel, Qatar, Saudi Arabia, South Africa, United Arab Emirates, Rest of MEA)

Asia-Pacific (Australia, Bangladesh, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Sri Lanka, Thailand, Taiwan, Rest of Asia-Pacific)

The Competitive Quadrant

The report includes the Competitive Quadrant, a proprietary tool to analyze and evaluate the position of companies based on their Industry Position score and Market Performance score. The tool uses various factors for categorizing the players into four categories. Some of these factors considered for analysis are financial performance over the last 3 years, growth strategies, innovation score, new product launches, investments, growth in market share, etc.

Ansoff Analysis

The report presents a detailed Ansoff matrix analysis for the Global White Biotechnology Market. Ansoff Matrix, also known as Product/Market Expansion Grid, is a strategic tool used to design strategies for the growth of the company. The matrix can be used to evaluate approaches in four strategies viz. Market Development, Market Penetration, Product Development and Diversification. The matrix is also used for risk analysis to understand the risk involved with each approach.

The Global White Biotechnology Market is analyzed using the Ansoff Matrix to provide the best approaches a company can take to improve its market position.

Based on the SWOT analysis conducted on the industry and industry players, suitable strategies have been devised for market growth.

Story continues

Why Buy This Report?

The report offers a comprehensive evaluation of the Global White Biotechnology Market. The report includes in-depth qualitative analysis, verifiable data from authentic sources, and projections about market size. The projections are calculated using proven research methodologies.

The report has been compiled through extensive primary and secondary research. The primary research is done through interviews, surveys, and observation of renowned personnel within the industry.

The report includes an in-depth market analysis using Porter's 5 forces model and the Ansoff Matrix. In addition, the impact of COVID-19 on the market is also featured in the report.

The report also includes the regulatory scenario within the industry, which will help you make a well-informed decision. The report discusses major regulatory bodies and major rules & regulations imposed on this sector across various geographies.

The report also contains competitive analysis using 'Positioning Quadrants'; a proprietary competitive positioning tool.

Market Dynamics

Drivers

Restraints

Opportunities

Increasing Investment in Biofuels

Biosynthesis of Nanomaterials by Microorganisms

Ban on the Use of Conventional Plastic

Advancement in White Biotechnology Through Fungi

Challenges

Avaliblity of the Alternatives

Shifting Consumer Preferences

Life Span and Limitation of Products

Key Topics Covered:

1 Report Description

2 Research Methodology

3 Executive Summary

4 Market Dynamics

5 Market Analysis

6 Global White Biotechnology Market, by Product

7 Global White Biotechnology Market, by Application

8 Americas' White Biotechnology Market

9 Europe's White Biotechnology Market

10 Middle East and Africa's White Biotechnology Market

11 APAC's White Biotechnology Market

12 Competitive Landscape

13 Company Profiles

14 Appendix

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/xsn84u

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-white-biotechnology-market-report-2022-cost-and-energy-consumption-advantage-compared-to-other-technologies-drives-growth-301636893.html

SOURCE Research and Markets

The rest is here:
Global White Biotechnology Market Report 2022: Cost and Energy Consumption Advantage Compared to Other Technologies Drives Growth - Yahoo Finance

Putnam Investments announced that on Friday, September 30, it will launch two new transparent, actively managed, equity exchange traded funds: the Putnam BDC Income ETF (NYSE Arca: PBDC), concentrating on business development companies (BDCs), and the Putnam BioRevolutionETF(NYSE Arca: SYNB), centered on companies operating at the intersection of technology and biology in the biology revolution.

PBDC will represent the first actively managed BDC ETF in the marketplace, investing in a host of BDC opportunities with an eye toward generating income for investors.

Putnam is excited to bring these two dynamic new strategies to market as we seek to address the long-term investment needs of advisors and their clients, said Robert L. Reynolds, president and CEO of Putnam Investments, in a news release. Our firm is focused on providing unique and differentiated offerings delivered through a variety of vehicles that tap Putnams deep investing expertise and exceptional research capabilities.

PBDC invests in exchange traded BDCs based in the U.S. and registered with the SEC. BDCs generally invest in, lend capital to, or provide services to privately held U.S. companies or thinly traded U.S. public companies. Putnam has managed a similar non-public BDC-focused strategy for nearly five years. The fund is managed by Michael Petro.

SYNB, meanwhile, invests in companies that seek to capitalize on the convergence of technological developments in the life sciences sector, including technology-enabling companies, synthetic biology companies, and companies that operate in industries that are likely to benefit from the biology revolution. The fund is managed by William Rives.

We have identified BDCs and advances in the biology sector as providing distinctive opportunities for investors in rapidly evolving sectors of the economy, added Carlo Forcione, head of product and strategy at Putnam Investments. Our new ETFs represent innovative, early-to-market offerings that will align well with the portfolio construction needs of our clients and the broader marketplace.

The new ETFs will join Putnams existing suite of four active ETFs that the firm launched in May 2021: the Putnam Focused Large Cap Growth ETF (NYSE Arca: PGRO), the Putnam Focused Large Cap Value ETF (NYSE Arca: PVAL), the Putnam Sustainable Future ETF (NYSE Arca: PFUT), and the Putnam Sustainable Leaders ETF (NYSE Arca: PLDR).

For more news, information, and strategy, visitVettaFi.

See the original post here:
Putnam Launches 2 Active ETFs Targeting BDCs and Biotechnology - ETF Trends